Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Voyager Therapeutics (VYGR) Receivables (2022 - 2025)

Voyager Therapeutics (VYGR) has disclosed Receivables for 4 consecutive years, with $1.9 million as the latest value for Q4 2025.

  • Quarterly Receivables fell 12.29% to $1.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Dec 2025, down 12.29% year-over-year, with the annual reading at $1.9 million for FY2025, 12.29% down from the prior year.
  • Receivables hit $1.9 million in Q4 2025 for Voyager Therapeutics, down from $4.0 million in the prior quarter.
  • In the past five years, Receivables ranged from a high of $83.5 million in Q4 2023 to a low of $1.9 million in Q4 2025.
  • Historically, Receivables has averaged $14.4 million across 4 years, with a median of $3.5 million in 2024.
  • Biggest five-year swings in Receivables: plummeted 97.39% in 2024 and later dropped 12.29% in 2025.
  • Year by year, Receivables stood at $10.2 million in 2022, then surged by 716.54% to $83.5 million in 2023, then tumbled by 97.39% to $2.2 million in 2024, then decreased by 12.29% to $1.9 million in 2025.
  • Business Quant data shows Receivables for VYGR at $1.9 million in Q4 2025, $4.0 million in Q3 2025, and $2.5 million in Q2 2025.